Table 1
Component: Lipid-392 | Catalog number: DCL0020 | mol%: 90 | Role: Ionizable carrier
sales@dcchemicals.com
Lipid-392
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Table 1
Component: POPE | Catalog number: DC65745 | mol%: 8.5 | Role: Helper phospholipid
Table 1
Component: DMG-PEG2000 | Catalog number: DC40169 | mol%: 1.5 | Role: PEG lipid
Table 2
Component: Lipid-392 | Molecular weight: 1275.05 | mol%: 90 | Mass per 100 mg total lipid: 92.085 mg | Mass per 100 mg Lipid-392: 100.000 mg
Table 2
Component: POPE | Molecular weight: 718.0 | mol%: 8.5 | Mass per 100 mg total lipid: 4.897 mg | Mass per 100 mg Lipid-392: 5.318 mg
Table 2
Component: DMG-PEG2000 | Molecular weight: 2507 | mol%: 1.5 | Mass per 100 mg total lipid: 3.018 mg | Mass per 100 mg Lipid-392: 3.277 mg
Table 3
Component: Lipid-392 | Molecular weight: 1275.05 | mol%: 50 | Mass per 100 mg total lipid: 70.600 mg | Mass per 100 mg Lipid-392: 100.000 mg
Table 3
Component: DSPC | Molecular weight: 790.15 | mol%: 10 | Mass per 100 mg total lipid: 8.750 mg | Mass per 100 mg Lipid-392: 12.394 mg
Table 3
Component: Cholesterol | Molecular weight: 386.65 | mol%: 38.5 | Mass per 100 mg total lipid: 16.485 mg | Mass per 100 mg Lipid-392: 23.350 mg
Table 3
Component: DMG-PEG2000 | Molecular weight: 2507 | mol%: 1.5 | Mass per 100 mg total lipid: 4.164 mg | Mass per 100 mg Lipid-392: 5.899 mg
Table 4
Parameter: Buffer | Reported information: 20 mM acetate, pH 4.0 (B6)
Table 4
Parameter: N/P | Reported information: 10, selected in the N/P screen
Table 4
Parameter: Mixing | Reported information: Rapid mixing of RNA-containing aqueous buffer with the ethanol lipid phase; aqueous:ethanol = 3:1 v/v. No microfluidic flow-rate setting is reported.
Table 4
Parameter: Incubation | Reported information: 10 minutes at room temperature after mixing
Table 4
Parameter: Buffer exchange | Reported information: Dialysis against 1×PBS, pH 7.4, for 4 h using a 100 kDa MWCO membrane
Table 4
Parameter: Size / morphology | Reported information: Cryo-TEM: well-dispersed spherical particles below 100 nm. DLS, PDI and EE are plotted in the SI; exact numerical means are not tabulated.
Table 4
Parameter: Apparent pKa | Reported information: 7.67 for the formulated stLNP, measured by TNS fluorescence with half-maximal fitted signal; pH 2.5–11, n=3.
Table 4
Parameter: Encapsulation | Reported information: RiboGreen; EE = (total RNA − free RNA) / total RNA ×100. No exact final value transcribed from a graph.
Table 4
Parameter: Physical stability | Reported information: SI S9 monitors size/PDI/EE through day 9; main text describes one week. Storage temperature and validated shelf life are not established by this result.
Table 5
Step: Ionizable lipid fraction | Selected condition: G8, 90 mol% Lipid-392 | Matched comparison: G4,50 mol% | Reported change: ~12-fold lung expression
Table 5
Step: Cholesterol removal | Selected condition: G8-5,90:8.5:0:1.5 | Matched comparison: G8-2,90:2:6.5:1.5 | Reported change: ~1.9-fold lung expression
Table 5
Step: Phospholipid | Selected condition: POPE,8.5 mol% | Matched comparison: DSPC,8.5 mol% | Reported change: ~1.7-fold lung expression
Table 5
Step: N/P | Selected condition: 10 | Matched comparison: 5/10/15/20 | Reported change: Author-selected condition; no exact fold assigned
Table 5
Step: Buffer | Selected condition: B6,20 mM acetate,pH4 | Matched comparison: B1,10 mM citrate,pH3 | Reported change: ~8-fold lung expression
Table 6
Group: G1 | Lipid-392: 0 | DSPC: 14.1 | Cholesterol: 54.4 | DMG-PEG2000: 1.5 | Sum mol%: 70.0
Table 6
Group: G2 | Lipid-392: 30 | DSPC: 14.1 | Cholesterol: 54.4 | DMG-PEG2000: 1.5 | Sum mol%: 100.0
Table 6
Group: G3 | Lipid-392: 40 | DSPC: 12.1 | Cholesterol: 46.4 | DMG-PEG2000: 1.5 | Sum mol%: 100.0
Table 6
Group: G4 | Lipid-392: 50 | DSPC: 10 | Cholesterol: 38.5 | DMG-PEG2000: 1.5 | Sum mol%: 100.0
Table 6
Group: G5 | Lipid-392: 60 | DSPC: 7.9 | Cholesterol: 30.6 | DMG-PEG2000: 1.5 | Sum mol%: 100.0
Table 6
Group: G6 | Lipid-392: 70 | DSPC: 5.9 | Cholesterol: 22.6 | DMG-PEG2000: 1.5 | Sum mol%: 100.0
Table 6
Group: G7 | Lipid-392: 80 | DSPC: 3.8 | Cholesterol: 14.7 | DMG-PEG2000: 1.5 | Sum mol%: 100.0
Table 6
Group: G8 | Lipid-392: 90 | DSPC: 1.8 | Cholesterol: 6.7 | DMG-PEG2000: 1.5 | Sum mol%: 100.0
Table 6
Group: G9 | Lipid-392: 100 | DSPC: 0 | Cholesterol: 0 | DMG-PEG2000: 0 | Sum mol%: 100
Table 7
Group: G8-1 | Lipid-392: 90 | DSPC: 0 | Cholesterol: 8.5 | DMG-PEG2000: 1.5 | N/P: 12
Table 7
Group: G8-2 | Lipid-392: 90 | DSPC: 2 | Cholesterol: 6.5 | DMG-PEG2000: 1.5 | N/P: 12
Table 7
Group: G8-3 | Lipid-392: 90 | DSPC: 4 | Cholesterol: 4.5 | DMG-PEG2000: 1.5 | N/P: 12
Table 7
Group: G8-4 | Lipid-392: 90 | DSPC: 6 | Cholesterol: 2.5 | DMG-PEG2000: 1.5 | N/P: 12
Table 7
Group: G8-5 | Lipid-392: 90 | DSPC: 8.5 | Cholesterol: 0 | DMG-PEG2000: 1.5 | N/P: 12
Table 8
Group: B1 | Buffer: Citrate | Concentration: 10 mM | pH: 3.0
Table 8
Group: B2 | Buffer: Citrate | Concentration: 20 mM | pH: 3.0
Table 8
Group: B3 | Buffer: Citrate | Concentration: 10 mM | pH: 4.0
Table 8
Group: B4 | Buffer: Citrate | Concentration: 20 mM | pH: 4.0
Table 8
Group: B5 | Buffer: Acetate | Concentration: 10 mM | pH: 4.0
Table 8
Group: B6 | Buffer: Acetate | Concentration: 20 mM | pH: 4.0
Table 9
Endpoint: Initial formulation screen | Finding: G8 (90 mol% Lipid-392) gave approximately 12-fold higher lung expression than G4 (50 mol%). | Experimental context / comparator: Luc mRNA 0.1 mg/kg IV; C57BL/6 mice; 6 h; n=3; N/P 12; comparator: Matched G1–G9 formulation series | Source: Fig. 1B–F; SI S2
Table 9
Endpoint: Cholesterol removal | Finding: G8-5 (90:8.5:0:1.5) gave approximately 1.9-fold higher expression than G8-2 (90:2:6.5:1.5). | Experimental context / comparator: Mouse IV luciferase screen; dose/time not separately restated in Fig.2 caption; n=3; Lipid-392/DSPC/cholesterol/DMG-PEG2000; N/P 12; comparator: G8-1 through G8-5 | Source: Fig. 2A–B; SI S4
Table 9
Endpoint: Phospholipid selection | Finding: POPE gave the greatest reported expression, approximately 1.7-fold versus DSPC. | Experimental context / comparator: Mouse IV luciferase screen; dose/time not separately restated in Fig.2 caption; n=3; Lipid-392/helper/DMG-PEG2000 90:8.5:1.5; N/P 12; comparator: DSPC, DOPC, 4ME, DOPE, POPE | Source: Fig. 2C–D; SI S5
Table 9
Endpoint: N/P selection | Finding: Authors selected N/P 10 for the POPE-containing three-component formulation. | Experimental context / comparator: Mouse IV luciferase screen; dose/time not separately restated in Fig.2 caption; n=3; comparator: N/P 5, 10, 15, 20 | Source: Fig. 2E–F; SI S6
Table 9
Endpoint: Buffer selection | Finding: B6 (20 mM acetate pH 4.0) produced approximately 8-fold higher lung expression than B1 (10 mM citrate pH 3.0). | Experimental context / comparator: Lipid-392 stLNP; IV luciferase screen; n=2; exact screen dose not restated in Fig. 3A–C caption; comparator: Six buffer conditions B1–B6 | Source: Fig. 3A–C; SI S8
Table 9
Endpoint: Matched lung benchmark | Finding: 4.93-fold higher lung luciferase signal; approximately 99% of measured lung/liver/spleen signal localized to lung. | Experimental context / comparator: Luc mRNA 0.25 mg/kg IV; 6 h; n=4; comparator: DOTAP-5-LNP | Source: Fig. 3F–G; Results p.15353
Table 9
Endpoint: RNA-loaded acute tolerability | Finding: Displayed ALT/AST and inflammatory markers were comparable to PBS; DOTAP-5-LNP elevated multiple markers. | Experimental context / comparator: Luc mRNA 1 mg/kg IV; 6, 24, 48 h; n=5; comparator: PBS and DOTAP-5-LNP | Source: Fig. 3H; SI S12
Table 9
Endpoint: High-dose empty particles | Finding: Transient liver-enzyme/cytokine elevations; highest-dose markers remained mildly elevated at 48 h. No overt distress or organ damage reported over the observation period. | Experimental context / comparator: EMPTY stLNP; lipid exposure equivalent to RNA doses 5, 8, 10, 12 mg/kg; IV; 6, 24, 48 h; n=3; comparator: PBS | Source: Fig. 2G–H; SI S7; Results p.15351
Table 9
Endpoint: Lung-cell uptake | Finding: Cy5-positive: approximately 82% endothelial, 78% epithelial and 50% total lung cells. This is uptake, not editing. | Experimental context / comparator: Cy5-labeled mRNA; IV; 6 h; n=3; dose CONFLICT: 0.3 mg/kg in Fig. 4A caption, 0.5 mg/kg in Results/Methods; comparator: PBS | Source: Fig. 4A–D; SI S13; Methods p.15358
Table 9
Endpoint: Cre reporter activation | Finding: tdTomato-positive: approximately 68% endothelial, 70% epithelial, 32% immune and 37% total lung cells. | Experimental context / comparator: Ai14 mice; Cre mRNA IV; 48 h; n=3; dose CONFLICT: 0.5 mg/kg in Fig. 4E caption, 0.3 mg/kg in Results/Methods; comparator: PBS | Source: Fig. 4E–H; Methods p.15358
Table 9
Endpoint: Single-dose kinetics | Finding: Luciferase signal detectable from 0.5 h to 48 h; the 48 h image uses a different color scale. | Experimental context / comparator: Luc mRNA 0.75 mg/kg IV; 0.5, 2, 6, 12, 24, 48 h; n=4; comparator: Within-formulation time course | Source: Fig. 5A–C
Table 9
Endpoint: Repeat dosing | Finding: Similar expression peaks were obtained after dosing every 48 h over three administrations. | Experimental context / comparator: Luc mRNA 0.75 mg/kg IV at 0, 48, 96 h; follow-up through 144 h; n=4; comparator: Repeated stLNP administration | Source: Fig. 5A/D–E
Table 9
Endpoint: Adenine base editing | Finding: 3.24% editing in lung tissue by NGS; separate from the much larger Cre reporter percentages. | Experimental context / comparator: ABE reporter mice; ABE mRNA:sgRNA 2:1 mass ratio; total RNA 1 mg/kg IV; day 5; n=3; comparator: PBS | Source: Fig. 5F–H; Methods p.15358
Table 9
Endpoint: Acute lung injury treatment | Finding: IL-10 delivery reduced TNF-alpha and IL-6 in lung tissue and BALF and improved histology. Empty LNP did not produce the same effect. | Experimental context / comparator: LPS-induced mouse ALI; IL-10 mRNA 1 mg/kg IV 2 h after induction; n=4; LPS dose and endpoint timing conflict between Results and Methods; comparator: Healthy, LPS/PBS, LPS/empty LNP | Source: Fig. 5I–K; SI S15–S16; Methods p.15358
Table 9
Endpoint: siTie2 knockdown | Finding: Lung Tie2 mRNA ED50 = 0.056 mg/kg; protein suppression also evaluated. | Experimental context / comparator: Single IV siTie2 dose-response; lung tissue at 72 h; n=3; exact dose range differs between plotted series and Methods list; comparator: PBS / dose-response | Source: Fig. 6A–C; Methods p.15359
Table 9
Endpoint: siEGFP knockdown | Finding: Approximately 50% lung EGFP mRNA knockdown with reduced reporter fluorescence. | Experimental context / comparator: EGFP reporter mice; IV; day 3; n=3; dose CONFLICT: 1 mg/kg in Fig. 6D caption, 2 mg/kg in Methods; comparator: LNP-only control | Source: Fig. 6D–F; Methods p.15359
Table 9
Endpoint: Particle characterization | Finding: Apparent LNP pKa 7.67 by TNS; spherical particles below 100 nm by cryo-TEM. No exact DLS mean assigned from a plotted bar. | Experimental context / comparator: Final stLNP; TNS half-maximal fitted fluorescence, pH 2.5–11; n=3; comparator: No isolated-lipid pKa measurement | Source: Fig. 3D–E
Table 9
Endpoint: Short-term physical stability | Finding: Main text describes one-week stability; SI S9 plots observations through day 9. No validated shelf life or storage temperature assigned. | Experimental context / comparator: Size, PDI and encapsulation monitored; n=3; comparator: Within-formulation time course | Source: SI S9; Results p.15353
Table 10
Item: Structure mapping | Evidence: SI Fig.S1 labels the final structure NNCC14; the figure caption and synthesis identify it as Lipid-392. NNCC14 is retained as a source-scheme alias.
Table 10
Item: Architecture | Evidence: N-methylbis(3-aminopropyl)amine-derived scaffold, three tertiary amines, three palmitoyl diacylhydrazide branches and one N-linked 2-hydroxydecyl arm. No ester linker is present.
Table 10
Item: Formula | Evidence: C74H147N9O7; explicitly reported and independently recovered from the depicted neutral structure.
Table 10
Item: Average molecular weight | Evidence: 1275.05; calculated from the verified neutral structure.
Table 10
Item: Salt / stereochemistry | Evidence: No isolated counterion or solvate assigned. The OH-bearing stereocenter is unspecified; no enantiopurity claim.
Table 10
Item: HRMS discrepancy | Evidence: SI reports [M+H]+ calculated 1275.15 and found 1275.1793. Toolkit theoretical value is 1275.1496; the approximately 23 ppm offset is unresolved without the raw spectrum.
Table 10
Item: Analytical record | Evidence: SI p.3 supplies 1H NMR shifts and ELSD-HPLC 96.30% for the research batch. This is not a certificate for a DC Chemicals lot.
Table 10
Item: Derived SMILES | Evidence: CCCCCCCCCCCCCCCC(=O)NNC(=O)CCN(CCCN(C)CCCN(CCC(=O)NNC(=O)CCCCCCCCCCCCCCC)CC(O)CCCCCCCC)CCC(=O)NNC(=O)CCCCCCCCCCCCCCC
Table 11
Issue: 1 | How it is handled: Published HRMS [M+H]+ calculated 1275.15, found 1275.1793; toolkit theoretical 1275.1496. The approximately 23 ppm difference remains unresolved without the raw spectrum. Depicted connectivity, route and reported neutral formula agree.
Table 11
Issue: 2 | How it is handled: Fig. 4 Cy5-mRNA dose 0.3 mg/kg versus Results/Methods 0.5 mg/kg; Cre dose 0.5 mg/kg versus Results/Methods 0.3 mg/kg. Do not silently swap these.
Table 11
Issue: 3 | How it is handled: ALI LPS induction: Results 2 mg/kg versus Methods 10 micrograms/mouse; endpoint 24 h after treatment versus 24 h after induction. Not presented as a fully resolved reproduction protocol.
Table 11
Issue: 4 | How it is handled: siEGFP dose: Fig. 6D 1 mg/kg versus Methods 2 mg/kg. siTie2 Methods dose list omits lower plotted doses.
Table 11
Issue: 5 | How it is handled: Initial G1 recipe sums to 70 mol% as printed. G9 has zero PEG despite the general fixed-PEG description. Neither is corrected by inference.
Table 11
Issue: 6 | How it is handled: DOTAP-5-LNP printed ratio sums to 100.1 because of rounding. No silently normalized mass recipe supplied.
Table 11
Issue: 7 | How it is handled: N/P definition does not unambiguously specify which lipid nitrogens are counted. No RNA mass-to-lipid conversion is supplied.
Table 11
Issue: 8 | How it is handled: No CAS, assigned stereochemistry, isolated counterion, commercial lipid pack prices, batch COA or raw spectral/source-data files supplied.
Table 11
Issue: 9 | How it is handled: S9 does not establish a neat-material or stock-solution shelf life; main text one week versus plot through day 9.
Table 11
Issue: 10 | How it is handled: Lipid-392 is the investigated lipid; G1–G9 and B1–B6 are formulations of that lipid, not different chemical compounds.